NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Forecast, Price & News $12.21 -0.09 (-0.73%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$11.91▼$12.3050-Day Range$12.21▼$13.8652-Week Range$9.10▼$14.10Volume1.63 million shsAverage Volume1.85 million shsMarket Capitalization$3.51 billionP/E RatioN/ADividend YieldN/APrice Target$15.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amicus Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside24.5% Upside$15.20 Price TargetShort InterestBearish6.84% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.60Based on 5 Articles This WeekInsider TradingSelling Shares$1.65 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.43) to $0.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 starsMedical Sector800th out of 965 stocksPharmaceutical Preparations Industry375th out of 446 stocks 2.3 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.20, Amicus Therapeutics has a forecasted upside of 24.5% from its current price of $12.21.Amount of Analyst CoverageAmicus Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.84% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Amicus Therapeutics has recently increased by 3.10%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Amicus Therapeutics is -1.28. Previous Next 2.6 News and Social Media Coverage News SentimentAmicus Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amicus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows4 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,654,873.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Amicus Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.43) to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -19.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -19.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 27.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amicus Therapeutics (NASDAQ:FOLD) StockAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.Read More FOLD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FOLD Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 1, 2023 | stocknews.comWhich of These 3 Biotech Stocks Are a Buy, Sell, or Hold?September 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 1, 2023 | finance.yahoo.comAmicus Therapeutics to Present at Upcoming Investor Conferences in September 2023August 29, 2023 | finance.yahoo.comAmicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023August 25, 2023 | seekingalpha.comAmicus Therapeutics: U.K. Approval Expands Global ReachAugust 21, 2023 | markets.businessinsider.comAmicus Therapeutics Names Simon Harford New CFO With Immediate EffectAugust 16, 2023 | finance.yahoo.comAmicus Therapeutics Inc (AM6.SG)September 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 15, 2023 | finance.yahoo.comAmicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United KingdomAugust 15, 2023 | finance.yahoo.comAmicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United KingdomAugust 9, 2023 | stocknews.comModerna (MRNA) vs. Amicus Therapeutics (FOLD): Which Biotech Stock Should You Add to Your Portfolio?August 9, 2023 | finance.yahoo.comAmicus (FOLD) Misses on Q2 Earnings, Raises Revenue GuidanceAugust 8, 2023 | finance.yahoo.comAmicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate UpdatesAugust 7, 2023 | seekingalpha.comAmicus Therapeutics Q2 2023 Earnings PreviewAugust 7, 2023 | finance.yahoo.comWhy Earnings Season Could Be Great for Amicus Therapeutics (FOLD)August 4, 2023 | finance.yahoo.comZacks.com featured highlights include First Watch Restaurant Group, VersaBank and Amicus TherapeuticsJuly 31, 2023 | finance.yahoo.comAmicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023July 23, 2023 | finance.yahoo.comAmicus Therapeutics' (NASDAQ:FOLD) investors will be pleased with their favorable 33% return over the last yearJuly 17, 2023 | finance.yahoo.comAmicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS RatingJuly 14, 2023 | stocknews.com3 Top Biotech Stocks to Purchase Right AwayJuly 11, 2023 | msn.comMorgan Stanley Reiterates Amicus Therapeutics (FOLD) Equal-Weight RecommendationJune 27, 2023 | finanznachrichten.deAmicus Therapeutics, Inc.: Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European UnionJune 27, 2023 | finance.yahoo.comAmicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European UnionJune 5, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Amicus (FOLD), Teladoc (TDOC) and Bristol Myers (BMY)June 4, 2023 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD): Is Breakeven Near?May 26, 2023 | seekingalpha.comFOLD Amicus Therapeutics, Inc.See More Headlines Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Company Calendar Last Earnings8/08/2023Today9/21/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees484Year Founded2002Price Target and Rating Average Stock Price Forecast$15.20 High Stock Price Forecast$17.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+24.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-236,570,000.00 Net Margins-52.85% Pretax Margin-55.06% Return on Equity-157.79% Return on Assets-25.43% Debt Debt-to-Equity Ratio3.53 Current Ratio2.72 Quick Ratio2.40 Sales & Book Value Annual Sales$329.23 million Price / Sales10.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book27.75Miscellaneous Outstanding Shares287,120,000Free Float281,091,000Market Cap$3.51 billion OptionableOptionable Beta0.86 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. John F. Crowley (Age 56)Exec. Chairman Comp: $1.88MMr. Bradley L. Campbell M.B.A. (Age 47)CEO, Pres & Director Comp: $984.09kMs. Ellen S. Rosenberg (Age 60)Chief Legal Officer & Corp. Sec. Comp: $733.94kMr. David M. Clark (Age 48)Chief People Officer Comp: $701.39kMs. Daphne E. Quimi CPA (Age 57)M.B.A., Sr. VP of Fin. Comp: $748.4kDr. Jeffrey P. Castelli (Age 51)Chief Devel. Officer Comp: $709.64kMr. Simon Nicolas Reade Harford (Age 62)Chief Financial Officer Ms. Samantha Prout (Age 45)Chief Accounting Officer & Controller Dr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSr. Director of Investor RelationsMore ExecutivesKey CompetitorsImmunoGenNASDAQ:IMGNMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSDynavax TechnologiesNASDAQ:DVAXIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsJohn F CrowleySold 6,044 sharesTotal: $78,934.64 ($13.06/share)John F CrowleySold 6,044 sharesTotal: $78,451.12 ($12.98/share)Bradley L CampbellSold 18,093 sharesTotal: $234,666.21 ($12.97/share)Alberta Investment Management CorpBought 13,544 shares on 8/24/2023Ownership: 0.005%Comerica BankBought 163,568 shares on 8/22/2023Ownership: 0.057%View All Insider TransactionsView All Institutional Transactions FOLD Stock - Frequently Asked Questions Should I buy or sell Amicus Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FOLD shares. View FOLD analyst ratings or view top-rated stocks. What is Amicus Therapeutics' stock price forecast for 2023? 5 Wall Street research analysts have issued 1-year price objectives for Amicus Therapeutics' shares. Their FOLD share price forecasts range from $11.00 to $17.00. On average, they predict the company's stock price to reach $15.20 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price. View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts. How have FOLD shares performed in 2023? Amicus Therapeutics' stock was trading at $12.21 at the start of the year. Since then, FOLD stock has increased by 0.0% and is now trading at $12.21. View the best growth stocks for 2023 here. When is Amicus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our FOLD earnings forecast. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03. The biopharmaceutical company had revenue of $94.50 million for the quarter, compared to analyst estimates of $89.57 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 157.79% and a negative net margin of 52.85%. What ETFs hold Amicus Therapeutics' stock? ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC). What is John F. Crowley's approval rating as Amicus Therapeutics' CEO? 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX). What is Amicus Therapeutics' stock symbol? Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD." Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.34%), JPMorgan Chase & Co. (4.72%), State Street Corp (3.89%), Point72 Asset Management L.P. (2.44%), Geode Capital Management LLC (1.90%) and Fiera Capital Corp (1.75%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amicus Therapeutics' stock price today? One share of FOLD stock can currently be purchased for approximately $12.21. How much money does Amicus Therapeutics make? Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.51 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis. How many employees does Amicus Therapeutics have? The company employs 484 workers across the globe. How can I contact Amicus Therapeutics? Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001. This page (NASDAQ:FOLD) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.